We are about to finally get a more formal presentation of the great news we have all been waiting to hear. Medivation Inc. and Astellas Pharma Inc. announced that data from their Phase 3 AFFIRM trial, evaluating MDV3100 in men with advanced prostate cancer, will be highlighted in a late-breaking oral presentation at the upcoming [...]
Considering yesterday's post about the problems with fentanyl patches today's post becomes even more scarey. The Food and Drug Administration (FDA) has made warns of opioid drug mix-up! According to the FDA pills, tablets, or caplets of Percocet and eight other opioid products packaged by Novartis for Endo Pharmaceuticals may have been mixed up, with [...]
Leslie from the Malecare Advanced Prostate Cancer On-line Support Group made a post today warning us that there have been significant malfunctions in fentanyl patches. Fentanyl patches are used to control severe pain, especially in men with very progressed advanced prostate cancer. According to the information posted some of these patches are malfunctioning causing accidental [...]
Researchers at Ohio State University report that they have developed a new mathematical model for men with advanced prostate cancer who are on androgen deprivation therapy (ADT). This model could guide future treatment decisions for men with advanced prostate cancer, specifically, helping to decide which men would benefit from ADT on an intermittent schedule (IADT). [...]
Yesterday, The American Cancer Society (ACS) released their annual cancer statistics for the United States. Specific to prostate cancer, they indicated an increase in projected new prostate cancer diagnosis, but a decrease in prostate cancer deaths. In 2011, the ACS projected 240,890 new cases of prostate cancer; in 2012 they are projecting 241,740 new diagnoses. [...]